Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Blog
  • CARDIOLOGY...

CARDIOLOGY UPDATE-ABSORB III TRIAL- 2015

Dr. Prem AggarwalWritten by Dr. Prem Aggarwal Published On 2015-12-04T14:44:47+05:30  |  Updated On 4 Dec 2015 9:14 AM GMT
CARDIOLOGY UPDATE-ABSORB III TRIAL- 2015

CARDIOLOGY UPDATES ABSORB III TRIAL-Everolimus-eluting bioresorbable scaffolds for CAD proven to be only non-inferior to Xience stent.The fully bioresorbable Absorb vascular scaffold elutes everolimus and was developed to improve long-term outcomes after stent implantation. In previous trials and registries, the Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) has been found...

CARDIOLOGY UPDATES

 

ABSORB III TRIAL-

Everolimus-eluting bioresorbable scaffolds for CAD proven to be only non-inferior to Xience stent.

The fully bioresorbable Absorb vascular scaffold elutes everolimus and was developed to improve long-term outcomes after stent implantation. In previous trials and registries, the Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) has been found to be similar to the Xience cobalt-chromium everolimus-eluting stent in terms of the rates of adverse events at 1 year after implantation, but these studies were underpowered for clinical endpoints. ABSORB III was a large-scale, multicenter trial to determine the relative safety and effectiveness of the Absorb BVS compared to the Xience stent in patients with coronary artery disease.

A total of 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to receive an Absorb BVS or a Xience stent.

The primary endpoint of target-lesion failure (TVF; cardiac death, target-vessel MI, or ischemia-driven target lesion revascularization) at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (difference, 1.7%; p=0.007 for non-inferiority and 0.16 for superiority).

No differences were seen in rates of cardiac death (0.6% for Absorb and 0.1% for Xience; p=0.29), target-vessel myocardial infarction (6.0% and 4.6%, respectively; p=0.18), or ischemia-driven TLR (3.0% and 2.5%, respectively; p=0.50).

Rates of angina, all revascularization, and ischemia-driven target vessel revascularization did not differ at 1 year.

Device thrombosis (definite or probable) was seen in 1.5% of patients in the Absorb group and in 0.7% of patients in the Xience group (p=0.13).

The investigators concluded that in this large study, the Absorb BVS was non-inferior to the Xience everolimus-eluting stent with respect to target lesion failure at 1 year or any of its individual components.

Also, no differences were seen in device thrombosis, angina occurrence or the need for revascularization.

The authors suggested that longer-term follow-up is needed since the benefits of a BVS are unlikely to be fully seen at only 1 year. Also, the ABSORB IV trial is designed to more precisely determine whether there are clinically-meaningful differences in 1-year rates of TLF between these 2 devices as this study was not adequately powered for subgroup testing or to determine differences in low-frequency events. ABSORB IV will also assess quality of life differences between devices.

In an editorial that accompanied the publication of the ABSORB III data, Dr. RA Byrne acknowledged that the concept of a self-degrading stent is “intuitively attractive,” but raised concern over the numerically higher rates of TVF and all its individual components in the BVS arm, even though the trial met its predefined criteria for noninferiority. He also noted the more than 2-fold higher rate of device thrombosis in the BVS arm.

“Most clinicians in everyday practice would not accept this degree of difference between two stents in their catheterization laboratories. This means that the clinical relevance of the finding of statistical noninferiority is open to question.”

The Absorb BVS is currently approved in India.

 

References


  • TCT 2015 Late-Breaking Clinical Trial: Everolimus-eluting bioresorbable vascular scaffolds in patients with CAD: The ABSORB III trial. Presented by D. Kereiakes on October 12, 2015.

  • Ellis SG, Kereiakes DJ, Metzger C, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; epublished October 12, 2015.

  • Bryne RA. Bioresorbable vascular scaffolds—Will promise become reality? N Engl J Med. 2015; epublished October 12, 2015.

Absorb III Cardiology Cardiology Updates everolimus eluting stents Stents Xience 
Dr. Prem Aggarwal
Dr. Prem Aggarwal

    MBBS,MD, DNB (Cardiology)

    Dr Prem Aggarwal, (DNB Cardiology) is an Cardiologist by profession and also the Co-founder of Medical Dialogues. An avid researcher, he is currently associated with GB Pant Hospital (GIPMER) New Delhi as a PhD Fellow pursuing his research on the topic of Angioplasties on Surgical Rejects

    Show Full Article

    More News

    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok